anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for preparing an injection which contains Ginkgo extracts comprises (a) dissolving 1 wt. part of Ginkgo extract and 0.1-10 wt. parts of a solution velocity increasing agent selected from povidone, mannitol, sorbitol, white sugar, glucose, dextrose or xylitol with 20-1,000 wt. parts of distilled water; (b) filtrating the resultant and refrigerating the obtd. residual solution at -10 deg.C or below; (c) drying it under reduced pressure to obtain powder; and (d) preparing an alkali soln. of pH 8-13 as a solvent which may be added into the powder to obtain an injection of pH 6.0-7.5.
The purpose of this study was to identify the target genes of tcon_00044595, elucidate its activation site, and provide novel insights into the pathogenesis and treatment of neonatal hypoxic-ischemic brain damage (HIBD). Through homologous blast analysis, we identified predicted target sequences in the neighboring regions of the long non-coding RNA (lncRNA) tcon_00044595, suggesting that limd1 is its target gene. Starbase was utilized to identify potential candidate microRNAs associated with the lncRNA. The interaction between the candidate microRNAs and limd1 was investigated and validated using various experimental methods including in vitro cell culture, cell transfection, dual fluorescence reporter detection system, and real-time PCR. Homology alignment analysis revealed that the lncRNA tcon_00044595 exhibited a 246 bp homologous sequence at the 3' end of the adjacent limd1 gene, with a conservation rate of 68%. Analysis conducted on Starbase online identified three potential microRNA candidates: miR-3471, miR-883a-5p, and miR-214-3p. Intracellular expression of the limd1 gene was significantly down-regulated upon transfection with miR-3471, while the other two microRNAs did not produce noticeable effects. Luciferase reporter assays identified two interaction sites (UTR-1, UTR-2) between miR-3471 and the limd1 3'UTR, with UTR-1 exhibiting a strong influence. Further CCK8 assay indicated a protective role of miR-3471 during low oxygen stroke in HIBD. The potential regulatory relationship between lncRNA (tcon_00044595), miR-3471, and the target gene limd1 suggests their involvement in the occurrence and development of HIBD, providing new insights for investigating the underlying mechanisms and exploring targeted therapeutic approaches for HIBD.
Embodiments relate to a diagnosis support system, a diagnosis support apparatus, and a diagnosis support method. So that medical information about the patient can be easily grasped. The diagnosis support system of the embodiment is provided with a storage unit, an extraction unit, a calculation unit, and a display control unit. The storage unit stores medical information including patient information related to a state of a patient and intervention information related to an intervention into the patient. The extraction unit extracts a change point of the medical information. The calculation unit calculates a first change amount indicating a change in the patient information before and after the change point and a second change amount indicating a change in the intervention information before and after the change point. The display control unit performs display based on the first variation and the second variation in a display mode set in accordance with at least one of the first variation and the second variation.
Participants will undergo smell retraining as described above. They will also complete budesonide irrigations once a day by pouring 0.5mg/2ml of budesonide into a irrigation bottle with saline and irrigating the nose.
Cancer-associated cachexia represents a multifactorial syndrome mainly characterized by muscle mass loss, which causes both a decrease in quality of life and anti-cancer therapy failure, among other consequences. The definition and diagnostic criteria of cachexia have changed and improved over time, including three different stages (pre-cachexia, cachexia, and refractory cachexia) and objective diagnostic markers. This metabolic wasting syndrome is characterized by a negative protein balance, and anti-cancer drugs like chemotherapy or immunotherapy exacerbate it through relatively unknown mechanisms. Due to its complexity, cachexia management involves a multidisciplinary strategy including not only nutritional and pharmacological interventions. Physical exercise has been proposed as a strategy to counteract the effects of cachexia on skeletal muscle, as it influences the mechanisms involved in the disease such as protein turnover, inflammation, oxidative stress, and mitochondrial dysfunction. This review will summarize the experimental and clinical evidence of the impact of physical exercise on cancer-associated cachexia.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to new derivatives of triazolebenzazepine of the general formula (I)  . Pharmaceutical antihistaminic composition has a compound of the formula (I) as an active component taken at therapeutically effective dose. Compounds of the formula (I) show antiallergic activity. Invention claims compounds of the formula (VII)  , its additive salts or stereochemically isomeric forms where each of dotted line means independently each of other optionally a bond, and compounds of the formula (XIII)  . Invention proposes eight methods of synthesis of compounds of the formula (I). Methods ensure to synthesize new valuable derivatives of triazole-benzazepine showing antiallergic activity and their using for preparing pharmaceutical compositions on their base for treatment of patients with allergic sicknesses. EFFECT: improved method of synthesis of new triazolebenzazepines, enhanced effectiveness of compounds. 17 cl, 26 ex
Inflammation-associated diseases encompass a range of infectious diseases and non-infectious inflammatory diseases, which continuously pose one of the most serious threats to human health, attributed to factors such as the emergence of new pathogens, increasing drug resistance, changes in living environments and lifestyles, and the aging population. Despite rapid advancements in mechanistic research and drug development for these diseases, current treatments often have limited efficacy and notable side effects, necessitating the development of more effective and targeted anti-inflammatory therapies. In recent years, the rapid development of nanotechnology has provided crucial technological support for the prevention, treatment, and detection of inflammation-associated diseases. Various types of nanoparticles (NPs) play significant roles, serving as vaccine vehicles to enhance immunogenicity and as drug carriers to improve targeting and bioavailability. NPs can also directly combat pathogens and inflammation. In addition, nanotechnology has facilitated the development of biosensors for pathogen detection and imaging techniques for inflammatory diseases. This review categorizes and characterizes different types of NPs, summarizes their applications in the prevention, treatment, and detection of infectious and inflammatory diseases. It also discusses the challenges associated with clinical translation in this field and explores the latest developments and prospects. In conclusion, nanotechnology opens up new possibilities for the comprehensive management of infectious and inflammatory diseases.
Disclosed are techniques for supporting glucoregulatory management decisions using a decision support recommender to predict an occurrence of a hypoglycemic event in an incognizant living subject. Glucose management data is obtained from a living subject. It is processed as prescribed by a feature extractor to generate a set of glucoregulatory feature values. The glucoregulatory feature values are applied as prescribed by the feature extractor to a hypoglycemia prediction model. The hypoglycemia prediction model is formulated to predict the occurrence of a hypoglycemic event during a period of incognizance of the living subject. A glucoregulatory management recommendation is generated as prescribed by the decision support recommender if the hypoglycemia prediction model predicts the occurrence of a hypoglycemic event during the period of incognizance.
PURPOSE:To obtain the titled compound having immune adjusting actions, growing action on nerve projection of cell and differentiation introducing ability, by reacting a specific sialic acid derivative with cholesterol and hydrolyzing the prepared reaction product. CONSTITUTION:A compound shown by formula I is reacted with cholesterol in a molar ratio of the former to the latter of usually 1:1-5. The reaction is usually carried out in the presence of a catalyst (e.g. silver trifluoromethanesulfonate, etc.) for Koenigs-Knorr reaction in a solvent such as THF, etc., at 20-25 deg.C. Then the prepared compound shown by formula II (one of R<1> and R<2> is -COOCH3 and the other is group shown by formula III) is treated with 1-3N sodium hydroxide solution at 15-25 deg.C for 5-15hr and hydrolyzed to give the aimed compound shown by formula IV (one of R<3> and R<4> is -COONa and the other is group shown by formula III).
PROBLEM TO BE SOLVED: To efficiently prepare a medical certificate by preparing the medical certificate synthesizing a diagnostic image based on diagnostic image information acquired from a reagent into a medical certificate format image which can describe character information. SOLUTION: A signal sampling part 2 samples a signal from a reagent 4 and based on that signal, an image is generated by an image generating means 6. The generated image is stored in a memory provided at the image generating means 6. An operator selects the desired image to be added to the medical certificate out of a tomograph. The selection of the image is performed by matching a cursor with the desired image and clicking it while operating a pointing device such as a mouse provided at an operating part 16. When a medical certificate display icon displayed on a screen is clicked, the medical certificate format image is read from the memory of an image processing means 8 and displayed. Since the medical certificate format image displays patient information such as the ID name and sex of a patient, labor for input work can be saved.
The gene coding for Pasteurella haemolytica leukotoxin can be cloned in a plasmid expressed in Escherichia coli. The leukotoxin gene can be isolated from a clone bank of P. haemolytica. The clone bank is constructed by partial digestion of genomic DNA. The resultant 5 to 10 kilobase-pair fragments are ligated into plasmid vector pBR322. The resultant clones are screened for the production of P. haemolytica soluble antigens by a colony enzyme-linked immunosorbent assay blot method with a rabbit antiserum raised against the soluble antigens. The clones producing P. haemolytica soluble antigens are then analyzed for the production of the leukotoxin by a cytotoxicity assay with cells from a bovine leukemia-derived B-lymphocyte cell line as the target cells. Positive clones are identified, and subsequent restriction analysis of the recombinant plasmids shows the same insert DNA is cloned in the plasmid vector. The DNA sequence analysis of the insert DNA reveals regions coding for the leukotoxin.
Hepatic artery pseudoaneurysms have been reported to occur in approximately 1% of cases after metal stenting for malignant biliary obstruction. In contrast, only a few cases have been reported as complications after plastic stenting for benign biliary disease. We report a 61-year-old man with cholangitis who presented with a rare complication of hemobilia after implantation of 7 Fr double pigtail plastic biliary stents. No bleeding was observed approximately one month after biliary stent tube removal. Contrast-enhanced CT scan revealed a circularly enhanced lesion (5 mm in diameter) in the arterial phase at the tip of the previously inserted plastic bile duct stent. Color Doppler ultrasonography enhanced the lesion and detected arterial blood flow inside. He was diagnosed with a hepatic artery pseudoaneurysm. However, he had no risk factors such as prolonged catheterization, severe cholangitis, liver abscess, or long-term steroid use. Superselective transarterial embolization using two metal microcoils was successfully completed without damage to the surrounding liver parenchyma. If hemobilia is suspected after insertion of a plastic bile duct stent, immediate monitoring using contrast-enhanced computed tomography or Doppler ultrasonography is recommended.
PROBLEM TO BE SOLVED: To obtain a hair-restoring food scarcely giving a side effect, excellent in safety and in hair restorability, and useful as an oral hair-restoring agent, etc., by adding proanthocyanidin as an active ingredient. SOLUTION: This hair-restoring food contains proanthocyanidin, a plant extract containing the proanthocyanidin as a main ingredient, or the purified product of the plant extract. The content of the proanthocyanidin is 0.1-50%, preferably 1-20%. The plant is a plant belonging to the genus Vitis, Malus, Hordeum, Cocos, Theobroma, Pinus, Phaseolus or Arachis. A hair-restoring food or an oral hair-restoring agent is preferably prepared by adding the alcohol fermentation product of a plant extract containing the proanthocyanidin or the purified product of the alcohol fermentation product as an active ingredient. The proanthocyanidin is preferably taken at a daily dose of 100-2,000 mg for an adult.
EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
The study aims to investigate acute effects of ballistic hamstring stretching, hamstring extender exercise, and kinesiotaping application on viscoelasticity of hamstrings and standing long jump performance on rowers. A total of 60 professional rowing athletes were included. Viscoelasticity of hamstrings were assessed by MyotonPRO, Tallinn, Estonia. Athletic performance was assessed by Standing Long Jump Test (SLJT). The athletes were randomly divided into Ballistic Hamstring Stretching Group (n= 20), Hamstring Extender Exercise Group (n= 20), and Kinesiotape Group (n= 20). For balistic hamstring stretching, athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute. For hamstring extender exercise, athletes were asked to apply the exercise 12 repetitions and 3 sets. Kinesiotaping was applied on the hamstring muscle with Y shape and 25% tension force.
1. The use of 5,6-dihydroxy-2-methylaminotetralin, or 5,6-diisobutyroyl-oxy-2-methyl-aminotetralin, or a pharmaceutically acceptable salt thereof in combination with an angiotensin-converting enzyme inhibitor for the preparation of a medicament for treating left ventricular dysfunction or remodeling. 2. The use according to claim 1 wherein said left ventricular remodeling is a consequence of myocardial infarction. 3. The use according to claim 1 wherein the angiotensin converting enzyme inhibitor is delapril. 4. The use of 5,6-dihydroxy-2-methylaminotetralin, 5,6-diisobutyroyl-oxy-2-methyl-aminotetralin, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the reducing of left ventricular remodeling, particularly congestive heart failure.
PROBLEM TO BE SOLVED: To obtain a 5-lipoxygenase inhibitor having good combination of excellent pharmacological action and good pharmacokinetics in vivo with intrinsic stability to metabolism and useful for the treatment of inflammatory diseases such as asthma by including a specific hydroxyurea compound having a specific steric chemical configuration. SOLUTION: This inhibitor contains preferably 0.1-90 wt.% (based on the whole composition) of a compound of formula I (R is a halogen or the like; Z is H or the like; M is H or the like) [e.g. N- (1S,4R)-cis-4-(4-fluorophenoxy)-2- cyclopenten-1-yl}-N-hydroxyurea]. The compound of formula I can be produced e.g. by reacting a compound of formula II with trimethylsilyl isocyanate, etc., in an inert solvent such as tetrahydrofuran preferably at 20-100 deg.C. The daily administration rate for the treatment of human inflammation is preferably about 0.5-10 mg/kg (body weight) in single or divided doses by oral administration.
A pharmaceutical product (100) comprises a container (102; 104) with a high-viscosity liquid pharmaceutical composition (122) comprising a therapeutically active agent contained therein, e.g. for the treatment of a dermatological disorder, such as psoriasis on the human scalp. The container has a tapered dispensing section (108) having a length of at least 25 mm. A lid (104) is provided for protecting the dispensing section, the lid defining a liquid tight seal when engaging a tip (110) of the dispensing section. An inner bottom portion of the container is curved for facilitating emptying of the container. The liquid may comprise at least 75% oil, and the container may be made essentially from high-density polyethylene to reduce penetration of oil into the container material.
Inactivated EBV-infected vaccine given at Week 0 and Week 4. This arm included all participants who were negative for Epstein-Barr Virus (EBV) at baseline.
A major obstacle to the development of effective CAR T-cells for T-cell malignancies is that the surface marker profile of malignant T-cells largely overlaps that of activated T lymphocytes. We developed a CAR T-cell approach that targets CD7, a T-cell marker highly expressed in all cases of T-cell ALL, including ETP-ALL. Its expression is also highly stable even in T-ALL cells exposed to chemotherapy. To prevent fratricide effect of the T cells, surface CD7 expression are effectively downregulated with the expression of an anti-CD7 Protein Expression Blocker (PEBL). Patients will receive anti-CD7 PEBL CART-cells. This will allow targeting the entire leukemia cell population to induce deeper and more durable remissions.
Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
The invention relates to a tracer for raising detection rate of sentinel lymph node of breast cancer and a preparation method of the preparation. The tracer is prepared as follows: 1ml 1% of methylthioninium chloride injection and 2.5ml 2% lidocaine hydrochloride injection are extracted by the use of a syringe; and normal saline is added to reach 5 ml so as to prepare a compound injection containing 0.2% methylene blue and 1% of lidocaine. A syringe is used to inject the prepared tracer in a point-like form under the skin around mammary areola of a patient's breast, and the total dosage of the tracer is 2ml to 4ml. Then, along the dilated blue-stained lymphatic vessels, all blue-stained lymph nodes are taken out to be inspected. The method has advantages of low cost, easy acquisition, no radiation, no requirement of special instrument detection and the like. By the method, detection rate of sentinel lymph node is raised, and cutaneous necrosis caused by methylene blue is avoided. The method is worth of popularization and application in various hospitals.
We intend to conduct a single-center randomized clinical trial that will enroll 90 patients planned for surgical treatment with a volar plate due to a displaced distal radius fracture in a day surgery setting. Patients who fulfill all of the inclusion criteria and none of the exclusion criteria (see below) will be approached by an MD and/or a RN in the study group on the day of surgery and provided with verbal and written information. If they give their informed written consent to participate in the study they will be randomized to either general or regional anesthesia. The ratio between the study arms will be 1:1 with 45 patients in each group. All patients will receive standard preoperative oral analgesics. Standard procedures for general and regional anesthesia will be used. The regional anesthesia used is supraclavicular brachial nerve block with short- and medium lasting local anesthetics. Patients who receive general anesthesia will be supervised on a postoperative intensive/intermediate care unit until they are stable and have an acceptable pain level before returning to a regular care unit. All patients leave the hospital on the day of surgery. Following standard procedures at our Orthopaedic department all patients will have a non-circular cast for about two weeks for pain-relieve. It will be removed at the standard two week check-up, at which time the sutures are removed, an X-ray is performed and the patients start non-weight bearing mobilization of the wrist.

The primary outcome is total opioid consumption during the first 72 hours postoperatively. It will be measured as the total amount of oral and iv opioids administered in the hospital before discharge as well as oral opioids that the patients consume after discharge. The patients will document their consumption of analgesics in a study diary and for the first three postoperative days report over telephone what they consumed during the previous 24 hours. For details on secondary outcomes see below. The patients will be interviewed over telephone during the first three postoperative days as well as at two weeks. Questions will include grading of pain on a 10 points VAS-scale, grading of postoperative nausea on a 10 points VAS-scale, if they have experienced postoperative vomiting, and if the would recommend the method of anesthesia to a friend or relative. The fractures will be classified by examining X-rays of the fractures before reduction. Postoperative X-rays will be examined and any remaining dislocation will be documented. The patients will fill out an injury-specific (PRWE) and a generic (EQ5D) form for health-related quality of life at the day of surgery (recall for the week before injury) and at 6 months. At 6 months an occupational therapist will perform a test of range of motion (ROM) and grip strength on all patients.

Furthermore, we intend to do an analysis of the resource utilization in the two groups. Time spent in pre-, peri- and postoperative units will be documented for each patient.

All personal data will be handled in a secure way according to ethical and legal regulations.
PURPOSE:To achieve a quick advance in the regeneration of a bone and a promotion of the bone formation by employing a piezo-electric porous film having communication holes with a specified value of an average diameter as bone formation inducing material. CONSTITUTION:A piezo-electric porous film composing a bone formation inducing material is made to have communicating holes with an average diameter of 0.1-5mum. The piezo-electric porous film comprises a composite of a piezo-electric porous molecular material, a polymer material and piezo-electric inorganic fine particles. Moreover, the piezo-electric polymer material herein used in a copolymer mainly composed of polyfluorovinylidene and vinylidene fluoride or a copolymer mainly composed of poly(lactic acid) or lactic acid. The piezo-electric inorganic fine particles herein used are lead zirconate titanate or barium titanate. The bone formation inducing material shows a quick formation of a bone and is useful clinically, especially since an alveolar bone can be regenerated quickly, thereby enabling application for an alveolar border forming operation.